Theranyx is a French biotech company founded in 2010 on a unique technology platform that has proved instrumental in the development of novel therapeutic solutions for the treatment of cancer.

Their mission is to discover, develop and commercialize new antibody fragments, mainly targeting cancers, with an improved efficiency and a lower toxicity than the compounds currently available to patients. As a proof of concept, Theranyx discovered 12 fully functional antibodies fragments, demonstrating an innovative pharmaceutical profile against two ion channels and two peptides receptors, for which patent applications have been submitted.

Bio-Connect Diagnostics supplies Theranyx products in the Benelux. If you have any questions about a product, please contact our helpdesk.

Major product lines

  • Purified membrane receptors
  • Ion channels/GPCR
  • Membrane receptor structure
  • VHH/nanobodies
  • Receptors over expressing inducible stable cell lines
For more information, please visit: